Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07635394, who can take part
Where in China
- Beijing Tiantan HospitalBeijing, ChinaContact: Fang LuoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07635394
- Record updated
- 25 June 2026
- Original description
To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).Read full original descriptionShow less
Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial
To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).
Inclusion: Age range: 18-70 years old; According to the Rome IV diagnostic criteria for IBS, the screening result is positive; Mild to moderate IBS patients assessed based on the IBS-SSS.
Exclusion: Concurrent gastrointestinal conditions presenting with symptoms potentially overlapping with those of IBS, significant medical comorbidities; Concomitant use of medications that may interact with the study drug, mimic its effects, or aggravate expected adverse reactions (including but not limited to rosiglitazone, pioglitazone, opioids, anxiolytics, non opioid analgesics, mexiletine, dextromethorphan, and sedative hypnotics); Severe mental disorders associated with marked personality disturbances, active suicidal thoughts or any self harm episodes within the preceding 12 months; Cognitive impairment; Recent use of pregabalin (within 30 days) or known allergy to pregabalin; Current or intended pregnancy or lactation; Use of IBS specific agents such as alosetron; Consumption exceeding 50 units of alcohol weekly (where 1 unit corresponds to 10 mL of pure alcohol).